Patients with cancer who are also suffering from psychiatric disorders are frequently being excluded from early phase oncology trials, according to recent findings published in the ‘General Hospital Psychiatry’. A new letter authored by a team of experts from the Paris Saclay University and Robert Debré Hospital in Paris, highlights the systemic barriers that limit access to innovative treatments for a significant subgroup of cancer patients.

The exclusion of these patients not only deprives them of potential therapeutic benefits but also raises concerns about equity in healthcare and the generalizability of study results. This news article delves into the intricacies of this issue and its implications for the future of oncology drug development, patient care, and ethical clinical practice.

The Study

The letter, titled “Exclusion of patients with psychiatric disorders from early phase oncology trials: A limited access to innovation?”, was authored by a team which includes Paul Matte (lead), Matthieu Delaye, Alice Mc Govern, Pascal Rouby, Santiago Ponce, Cédric Lemogne, and Capucine Baldini. It was assigned the DOI 10.1016/j.genhosppsych.2024.01.002 and is set to be part of the January 2024 issue of the esteemed ‘General Hospital Psychiatry’ journal.

The Findings

The team reviewed the criteria for inclusion in early-phase clinical trials, focusing on those related to psychiatric conditions. They found that these criteria often exclude patients with a history of psychiatric disorders, on the grounds that these individuals might not be able to provide informed consent or comply with trial protocols. However, the authors argue that advances in psychiatric care and psycho-oncology services have enhanced the capacity of these patients to participate in complex medical research.

Implications for Patient Care

This exclusion has significant implications for the care of cancer patients with psychiatric disorders. For starters, it limits their access to the newest therapies which might be more effective or less toxic than current options. Additionally, psychiatric symptoms often worsen due to cancer therapies, making it crucial for these patients to access treatments under development that could potentially alleviate their overall health condition.

The Ethics of Exclusion

The ethics of excluding a subgroup of patients from experimental treatments due to their psychiatric condition raises questions of fairness and justice. The ability to participate in clinical trials is not only about accessing potential new treatments but also about having the autonomy to make that choice and contributing to science.

The Generalizability of Clinical Trial Results

Generalizability, or the applicability of clinical trial results to the larger population, is another concern. By systematically excluding patients with psychiatric disorders, the trial results may not accurately reflect the drug’s efficacy and safety profile for this subgroup, which is a significant omission given the prevalence of psychiatric conditions among cancer patients.

Addressing the Barrier

To counter this issue, the authors call for more inclusive criteria in early phase oncology trials that consider the capabilities of modern psychiatric care. Moreover, oncology teams should work closely with psychiatric professionals to ensure that patients with psychiatric disorders can safely and effectively participate in clinical trials.

The Emerging Debate

This article is likely to spark a larger debate in the medical community about inclusion criteria in clinical trials and how they can be made fairer without compromising the integrity of the research. This is especially pertinent in light of the push for personalized medicine, which aims to tailor treatments to individual patient characteristics, including their mental health status.


1. Psychiatric disorders in clinical trials
2. Oncology trial exclusions
3. Early phase cancer research
4. Equity in healthcare access
5. Psycho-oncology advancements


1. DOI: 10.1016/j.genhosppsych.2024.01.002 – Matte, P. P., Delaye, M. M., Govern, A. M., Rouby, P., Ponce, S., Lemogne, C., & Baldini, C. (2024). Exclusion of patients with psychiatric disorders from early phase oncology trials: A limited access to innovation? General Hospital Psychiatry.

2. Rosch, K. E., Farberov, M., & Doward, J. (2020). Ethical considerations in oncology: Balancing the needs of patients, researchers, and society. Oncology.

3. Shim, J. K., & Russ, A. J. (2014). The ethical implications of stratified cancer care: Who gets the benefit of the doubt and who gets doubt of the benefit? Sociology Compass, 8(6), 796-811.

4. Roberts, L. W., Warner, T. D., & Dunn, L. B. (2000). Ethical considerations in oncology: Conceptualizing and treating cancer patients with psychiatry comorbidity. Harvard Review of Psychiatry, 8(4), 185-193.

5. Insel, T. R., & Scolnick, E. M. (2006). Cure therapeutics and strategic prevention: Raising the bar for mental health research. Molecular Psychiatry, 11(1), 11-17.

This in-depth report seeks to highlight a significant and often overlooked issue that affects patient care and trial results. It poses questions crucial to the evolution of ethical standards in clinical trial design, advocating for broader discussions on equity and inclusion in cancer research. The authors hope to open doors for many cancer patients who have been previously shut out from cutting-edge therapeutic advancements due to the co-existence of psychiatric conditions.